Emilie Bousquet

Montpellier, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Erratum: Efficacy and safety of SENS-501, a dual-AAV otoferlin gene therapy, for DFNB9 congenital deafness.

Erratum: Efficacy and safety of SENS-501, a dual-AAV otoferlin gene therapy, for DFNB9 congenital deafness.

Journal: Molecular therapy. Advances

Published: August 07, 2026

Efficacy and safety of SENS-501, a dual-AAV otoferlin gene therapy, for DFNB9 congenital deafness.

Efficacy and safety of SENS-501, a dual-AAV otoferlin gene therapy, for DFNB9 congenital deafness.

Journal: Molecular therapy. Advances

Published: December 04, 2025

Epidemiological disparities in pulmonary sarcoidosis between public and private healthcare sectors in haute-Garonne department (France).

Epidemiological disparities in pulmonary sarcoidosis between public and private healthcare sectors in haute-Garonne department (France).

Journal: Respiratory medicine and research

Published: January 11, 2025

RIP140 regulates transcription factor HES1 oscillatory expression and mitogenic activity in colon cancer cells.

RIP140 regulates transcription factor HES1 oscillatory expression and mitogenic activity in colon cancer cells.

Journal: Molecular oncology

Published: June 28, 2023

Generation and Characterization of a New Preclinical Mouse Model of EGFR-Driven Lung Cancer with MET-Induced Osimertinib Resistance.

Generation and Characterization of a New Preclinical Mouse Model of EGFR-Driven Lung Cancer with MET-Induced Osimertinib Resistance.

Journal: Cancers

Published: May 19, 2021

The evolution of resistance and tolerance as cancer defences.

The evolution of resistance and tolerance as cancer defences.

Journal: Parasitology

Published: November 16, 2019

Incidence of thyroid dysfunctions during treatment with nivolumab for non-small cell lung cancer: Retrospective study of 105 patients.

Incidence of thyroid dysfunctions during treatment with nivolumab for non-small cell lung cancer: Retrospective study of 105 patients.

Journal: Presse medicale (Paris, France : 1983)

Published: March 02, 2018

An oligoclonal antibody durably overcomes resistance of lung cancer to third-generation EGFR inhibitors.

An oligoclonal antibody durably overcomes resistance of lung cancer to third-generation EGFR inhibitors.

Journal: EMBO molecular medicine

Published: December 08, 2017

The RAS-related GTPase RHOB confers resistance to EGFR-tyrosine kinase inhibitors in non-small-cell lung cancer via an AKT-dependent mechanism.

The RAS-related GTPase RHOB confers resistance to EGFR-tyrosine kinase inhibitors in non-small-cell lung cancer via an AKT-dependent mechanism.

Journal: EMBO molecular medicine

Published: December 23, 2016

Development of Papulopustular Rosacea during Nivolumab Therapy for Metastatic Cancer.

Development of Papulopustular Rosacea during Nivolumab Therapy for Metastatic Cancer.

Journal: Acta dermato-venereologica

Published: November 09, 2016

RhoB determines tumor aggressiveness in a murine EGFRL858R-induced adenocarcinoma model and is a potential prognostic biomarker for Lepidic lung cancer.

RhoB determines tumor aggressiveness in a murine EGFRL858R-induced adenocarcinoma model and is a potential prognostic biomarker for Lepidic lung cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: October 17, 2014

Showing 1-11 of 11

Last Updated: 09/26/2026